Details for Patent: 12,233,042
Which drugs does patent 12,233,042 protect, and when does it expire?
Patent 12,233,042 protects YCANTH and is included in one NDA.
This patent has twenty patent family members in ten countries.
Summary for Patent: 12,233,042
| Title: | Treatment of cutaneous disorders |
| Abstract: | Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin. |
| Inventor(s): | Howard Welgus, Matthew Gene Davidson, Jayson Michael Rieger |
| Assignee: | Verrica Pharmaceuticals Inc |
| Application Number: | US17/471,853 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,233,042 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Device; |
Drugs Protected by US Patent 12,233,042
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verrica Pharms | YCANTH | cantharidin | SOLUTION;TOPICAL | 212905-001 | Jul 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TOPICAL TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,233,042
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018281313 | ⤷ Start Trial | |||
| Australia | 2024204696 | ⤷ Start Trial | |||
| Australia | 2026204209 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
